Akebia

Servier Pharmaceuticals LLC, located in Boston, MA, is dedicated to improving patient care through innovation and collaboration in the pharmaceutical sector. The company focuses on advancing therapies for various conditions, including acute lymphoblastic leukemia, acute myeloid leukemia, and glioma, among others. Committed to corporate responsibility, Servier actively seeks partnerships to enhance its pipeline and drive clinical trials aimed at bringing new medicines to market. The organization emphasizes transparency and patient engagement, ensuring that personal information is handled with the utmost care and respect. Generated from the website

Radius Health, Inc. is a biopharmaceutical company based in Boston, MA, focused on transforming the future of bone health for underserved patient populations. With a commitment to innovation, the company prioritizes patient well-being, evidenced by the launch of its first commercial product, TYMLOS, and subsequent expansions in its portfolio. Rooted in a culture of agility and integrity, Radius emphasizes a collaborative environment where employees are encouraged to bring their best to their work. The leadership team, comprised of experienced professionals from various sectors of the pharmaceutical industry, is dedicated to advancing the company's mission and enhancing the lives of patients. Generated from the website

Vigeo Therapeutics Inc is a clinical-stage biopharmaceutical company based in Boston, MA, dedicated to developing innovative therapeutics for various types of cancer. Their approach involves reprogramming the tumor immune microenvironment (TIME) to enhance cancer treatment outcomes. By activating thrombospondin-1 (Tsp-1), a natural anti-tumorigenic protein, Vigeo aims to target cancer cells and inhibit metastasis through CD36 and CD47 pathways. Vigeo Therapeutics is currently conducting clinical trials for VT1021, a peptide therapeutic agent, in patients with pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high levels of CD36. Their commitment to advancing cancer treatment is evident through their recent clinical updates and presentations, showcasing their progress in the field of oncology.Generated from the website